Quoin Pharmaceuticals, Ltd. American Depositary Shares closed at $3.75 on Nov 12, down 0.27%, 83.2% below its 52-week closing high. Volume of 5.5K shares was 0.42× its 20-day average (below normal).
Split-adjusted performance: -8.5% over one month, -35.5% over six months, -67.4% over one year.
Short interest was 23.7K shares at the Oct 30 settlement, up 17.2% from the prior report (1.9 days to cover).
No reported quarters with price history yet.
Percentile among 419 companies (100 = best)
Industry medians: 6-month return −26.6%, revenue growth +10.0%, net margin −36.2%, P/E 17.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| QNRXQuoin Pharmaceuticals | $3.75 | −0.27% | −35.5% | — | — | — | $18.0M | |
| AKTXAkari Therapeutics plc ADR (0.01 USD) | $6.51 | −12.62% | +75.9% | — | — | — | $14.9M | Compare |
| CMMBChemomab Therapeutics Ltd. American Depositary Share | $1.40 | +3.70% | −17.6% | — | — | — | $11.3M | Compare |
| MREOMereo BioPharma Group | $0.3050 | −0.52% | +24.0% | — | — | — | $48.7M | Compare |
| KZIAKazia Therapeutics Limited | $6.95 | −6.46% | −49.7% | — | — | — | $108.1M | Compare |
| BCYCBicycle Therapeutics | $3.45 | −6.50% | −26.1% | +190.2% | −30.8% | — | $241.8M | Compare |
| AMRNAmarin | $11.67 | −0.34% | −21.0% | −20.4% | 0.6% | — | $490.6M | Compare |
| SLNSilence Therapeutics Plc American Depository Share | $19.80 | +0.15% | +177.7% | — | — | — | $1.23B | Compare |
| CMPSCOMPASS Pathways Plc American Depository Shares | $9.12 | −1.94% | −14.1% | — | — | — | $1.29B | Compare |
No recent articles focused on Quoin Pharmaceuticals.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
